Form 4: Cue Biopharma Director Acquires Stock Options

Cue Biopharma, Inc. reports that Director Daniel A. Camardo acquired stock options on May 30, 2026, as detailed in a Form 4 filing.

Summary

• Daniel A. Camardo, a Director at Cue Biopharma, Inc., acquired stock options on May 30, 2026.
• The transaction involved 1,626 stock options with an exercise price of $21.90.
• These options are exercisable starting May 29, 2036.
• The underlying securities are 1,626 shares of Common Stock.
• The acquired options are held directly by Mr. Camardo.
• Vesting of the shares underlying the options is scheduled over three years, with one-third vesting on the one-year anniversary of the grant date and the remainder vesting in eight equal quarterly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a common practice and does not inherently indicate positive or negative performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule indicates a long-term commitment from the director.

Future Outlook

The filing details the terms of stock options granted to a director, including vesting schedules, which implies a long-term incentive structure and potential future share issuance.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means to attract and retain executive talent and align their interests with shareholders, especially during periods of development and potential growth.

Stakeholder Impact

• Shareholders: The grant of options to a director, with a vesting schedule, aligns the director's interests with long-term shareholder value creation. The exercise price and potential future dilution should be considered.

Key Dates

Keywords

Form 4, SEC Filing, Cue Biopharma, CUE, Stock Options, Director, Beneficial Ownership, Insider Trading